Saram ConsultingGxP & AI Consulting for Life Sciences. Custom AI integrations, Part 11 compliance validation, and equity-based engineering partnerships for biotech.Explore Services at saram.io →
← Back to Home

ADC Therapeutics

NYSE: ADCT ↗$1.22 USD~$300M MCAP
#Diffuse Large B-Cell Lymphoma (DLBCL)#Hematologic Malignancies#Solid Tumors#Antibody-Drug Conjugates#Targeted Oncology

ADC Therapeutics is a commercial-stage biopharmaceutical company developing antibody-drug conjugates (ADCs) for the treatment of hematologic cancers and solid tumors. Its lead product Zynlonta (loncastuximab tesirine) is the first CD19-targeted ADC approved for relapsed/refractory diffuse large B-cell lymphoma. The company is advancing a pipeline of next-generation ADCs targeting both hematologic malignancies and selected solid tumors.

Company Info

Sector:Biotechnology / Oncology (Antibody-Drug Conjugates)
Headquarters:Lausanne, Switzerland (with U.S. operations in Murray Hill, New Jersey)
Founded:2011
Website:www.adctherapeutics.com/

Upcoming Milestones & Key Dates

H2 2026
Regulatory

FDA Oncologic Drugs Advisory Committee meeting on Zynlonta confirmatory data interpretation

Q3 2026
Earnings

Q2 2026 earnings and Zynlonta commercial update

Clinical Development Pipeline

Zynlonta (loncastuximab tesirine)

Target: CD19-targeted pyrrolobenzodiazepine (PBD) dimer ADC
Relapsed/refractory diffuse large B-cell lymphoma (DLBCL)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

ADCT-602 (loncastuximab tesirine in combo)

Target: CD19-targeted PBD ADC
Relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

ADCT-901

Target: KAAG1-targeting ADC
Solid tumors (renal cell carcinoma, others)
Preclinical
Phase 1
Phase 2
Phase 3
Approved

Recent News

Leadership Team

Ameet Mallik

Chief Executive Officer

Ron Squarer

Chairman of the Board

Dr. Jay Feingold

Chief Medical Officer

Careers & Job Openings

See all open roles

Multiple Departments
See careers page
Apply Now →